Results 121 to 130 of about 2,495,770 (164)

Análise de componentes do sistema renina-angiotensina-aldosterona em cães com doença renal crônica [PDF]

, 2019
openaire   +1 more source

Arterial Stiffness, Clinical-Functional Outcomes, and Quality of Life in Post-COVID-19 Patients: A Cross-Sectional Study. [PDF]

Arq Bras Cardiol
Luna BC, Lamezon AC, Lima Junior E, Rabelo LM, Valderramas S.   +4 more
europepmc   +1 more source

[Cirrhotic cardiomyopathy – Clinically fact or academic curiosity? Review. Part 3: treatment] [PDF]

Rev Fac Cien Med Univ Nac Cordoba
Ramos H, Altieri M.
europepmc   +1 more source

The Effect of Early Administration of Hypertonic Saline Solution İn Acute Decompensated Heart Failure. [PDF]

Arq Bras Cardiol
Colluoglu T, Kapanşahin T, Aksu MH, Önalan O, Akin Y.   +4 more
europepmc   +1 more source

Heart Failure in Brazil: How Can We Improve its Natural History? [PDF]

Arq Bras Cardiol
Ferrari F, Rossi AP, Santander IRMF.
europepmc   +1 more source

Natriuretic Peptides and Heart Stress: Time to Screen the Asymptomatic High-Risk Population to Prevent Incident Heart Failure? [PDF]

Arq Bras Cardiol
Villacorta H, Souza DG, Jorge AJL.
europepmc   +1 more source

El uso de la enzima convertidora de angiotensina y de inhibidores del sistema renina angiotensina aldosterona ¿Podría ser una práctica beneficiosa en pacientes con COVID-19?

Revista Cubana de Cardiología y Cirugía Cardiovascular, 2020
Amet Amat Aliaga, Reinaldo de la Noval Garcia., Damaris Hernandez Veliz   +2 more
doaj  

[Association between hemodynamic parameters, insulin resistance, and body composition in primary care]. [PDF]

Aten Primaria
Mill Ferreyra EÓ, Verde de García RL, Azuara Azuara M, Zarza Fernández AM, Rodríguez Arce M, Pérez Coca C.   +5 more
europepmc   +1 more source

Assessment of allopurinol use in patients with chronic kidney disease and asymptomatic hyperuricemia: a retrospective cohort study. [PDF]

J Bras Nefrol
Souza MELS, Heringer TA, Schneider APH, Possuelo LG, Valim ARM.   +4 more
europepmc   +1 more source

Kidney effects of Glucagon-Like Peptide 1 (GLP1): from molecular foundations to a pharmacophysiological perspective. [PDF]

J Bras Nefrol
Rico-Fontalvo J, Reina M, Soler MJ, Unigarro-Palacios M, Castañeda-González JP, Quintero JJ, Raad-Sarabia M, Moraes TP, Daza-Arnedo R.   +8 more
europepmc   +1 more source